CompletedNCT01081769
Monthly paliperidone injection or oral antipsychotic treatment to prevent relapse in schizophrenia
About this title
Read the official source — NCT01081769Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Vienna and 93 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateFebruary 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 769
- Sponsor
- Janssen-Cilag International NV
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Belgium, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01081769
- Official title
Show the full official title
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antipsychotic Monotherapy in Adults With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Vienna, Austria · Bertrix, Belgium · Ghent, Belgium
94 more locations
- Liège, Belgium
- Ostend, Belgium
- Burgas, Bulgaria
- Plovdiv, Bulgaria
- Radnevo, Bulgaria
- Zagreb, Croatia
- Brno, Czechia
- Litoměřice, Czechia
- Olomouc, Czechia
- Prague, Czechia
- Přerov, Czechia
- Alexandria, Egypt
- Cairo, Egypt
- Talinn, Estonia
- Tartu, Estonia
- Colombes, France
- La Seyne-sur-Mer, France
- Limoges, France
- Metz, France
- Paris, France
- Saint-Avé, France
- Berlin, Germany
- Bochum, Germany
- Mannheim, Germany
- München, Germany
- Thessalonikis, Greece
- Budapest, Hungary
- Kalocsa, Hungary
- Nagykálló, Hungary
- Sopron, Hungary
- Bat Yam, Israel
- Beer Yaakov, Israel
- Hod HaSharon, Israel
- Ramat Gan, Israel
- Tirat Hacarmel, Israel
- Amman, Jordan
- Šiauliai, Lithuania
- Vilnius, Lithuania
- Chełmno, Poland
- Gdansk, Poland
- Torun, Poland
- Ząbki, Poland
- Arad, Romania
- Bucharest, Romania
- Jebel, Romania
- Oradea, Romania
- Sibiu, Romania
- Ekaterinburg Na, Russia
- Krasnodar, Russia
- Nizny Novgorod, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Tomsk, Russia
- Yaroslavl, Russia
- Bratislava, Slovakia
- Michalovce, Slovakia
- Rimavská Sobota, Slovakia
- Cape Town, South Africa
- Pretoria, South Africa
- Goyang, South Korea
- Incheon, South Korea
- Kyounggi, South Korea
- Seoul, South Korea
- Barcelona, Spain
- Burgos, Spain
- Elche, Spain
- Madrid, Spain
- Sant Boi de Llobregat, Spain
- Zamora, Spain
- Taichung, Taiwan
- Taipei, Taiwan
- Taoyuan, Taiwan
- Istanbul, Türkiye
- Manisa Turkey, Türkiye
- Zonguldak, Türkiye
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Hlevakha, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kiev, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Simferopol, Ukraine
- Uzhhorod, Ukraine
- Birmingham, United Kingdom
- Exeter, United Kingdom
- London, United Kingdom
- Warrington, United Kingdom
- Czechia
- Russia
- Türkiye
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Janssen-Cilag International NV.
Did this study involve medication?
Yes. The study involved medication, including paliperidone palmitate injection and oral antipsychotics.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia